Credit: Reuters/Arnd Wiegmann
The logo of Japanese Takeda Pharmaceutical Co is seen at an office building in Glattbrugg near Zurich March 7, 2012.
Consolidation therapy is given to cancer patients who have undergone initial therapy and kills any cancer cells that may be left in the body.
The trial showed that patients who received the drug, adcetris, immediately after a stem cell transplantation lived significantly longer without the disease progressing than those who were given a placebo, the companies said in a joint statement.
Adcetris is currently approved in 45 countries for the treatment of relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma, another type of cancer.
(Reporting by Anjali Rao Koppala in Bangalore; Editing by Savio D'Souza)
